BRPI0607119A2 - construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse - Google Patents
construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesseInfo
- Publication number
- BRPI0607119A2 BRPI0607119A2 BRPI0607119-8A BRPI0607119A BRPI0607119A2 BR PI0607119 A2 BRPI0607119 A2 BR PI0607119A2 BR PI0607119 A BRPI0607119 A BR PI0607119A BR PI0607119 A2 BRPI0607119 A2 BR PI0607119A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- delivery device
- mediated delivery
- particle mediated
- promoter sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
CONSTRUçãO DE áCIDO NUCLEICO, POPULAçãO DE CONSTRUçõES DE áCIDO NIJCLEICO, SEQUENCIA PROMOTORA QUIMéRICA ISOLADA PURIFICADA, PARTìCULAS REVESTIDAS, RECEPTáCULO DE DOSAGEM PARA UM DISPOSITIVO DE LIBERAçãO MEDIADA POR PARTìCULA, DISPOSITIVO DE LIBERAçãO MEDIADA POR PARTìCULA, COMPOSIçãO FARMACêUTICA, COMPOSIçãO DE VACINA, E, MéTODO IN VITRO DE OBTER A EXPRESSãO EM CéLULAS DE MAMìFERO DE UM POLIPEPTìDEO DA INFLUENZA DE INTERESSE. Uma construção de ácido nucleico que compreende uma seqüência promotora quimérica e um sítio de clonagem para a inserção de uma seqüência codificadora em ligação operável com o promotor quimérico, em que a seqUência promotora quimérica compreende: (a) uma seqUência promotora inicial imediata de hCMV; (b) exon 1 e pelo menos uma parte do exon 2 do gene inicial imediato maior de hCMV; e (c) um íntron heterólogo fornecido no lugar da região de íntron A do gene inicial imediato maior de hCMV.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64838205P | 2005-02-01 | 2005-02-01 | |
US67249705P | 2005-04-19 | 2005-04-19 | |
GBGB0507997.5A GB0507997D0 (en) | 2005-02-01 | 2005-04-20 | Nucleic acid constructs |
PCT/GB2006/000344 WO2006082398A2 (en) | 2005-02-01 | 2006-02-01 | Nucleic acid constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607119A2 true BRPI0607119A2 (pt) | 2009-08-11 |
Family
ID=36178086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607119-8A BRPI0607119A2 (pt) | 2005-02-01 | 2006-02-01 | construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse |
Country Status (20)
Country | Link |
---|---|
US (1) | US20100221349A1 (pt) |
EP (1) | EP1850869A2 (pt) |
JP (1) | JP2008528020A (pt) |
KR (1) | KR20070100403A (pt) |
CN (1) | CN101155597A (pt) |
AP (1) | AP2007004137A0 (pt) |
AU (1) | AU2006210716A1 (pt) |
BR (1) | BRPI0607119A2 (pt) |
CA (1) | CA2596731A1 (pt) |
EA (1) | EA011557B1 (pt) |
GB (1) | GB0507997D0 (pt) |
IL (1) | IL184653A0 (pt) |
MA (1) | MA29274B1 (pt) |
MX (1) | MX2007009164A (pt) |
NI (1) | NI200700191A (pt) |
NO (1) | NO20074421L (pt) |
SG (1) | SG158902A1 (pt) |
TN (1) | TNSN07295A1 (pt) |
WO (1) | WO2006082398A2 (pt) |
ZA (1) | ZA200707522B (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA010056B1 (ru) * | 2003-10-10 | 2008-06-30 | Паудерджект Вэксинс, Инк. | Конструкции нуклеиновых кислот |
CA2632261A1 (en) * | 2005-12-05 | 2007-06-14 | Guava Technologies | Particle-based analyte characterization |
EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
CA2715078C (en) * | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
MX2010005229A (es) | 2007-11-12 | 2010-11-05 | Univ Pennsylvania | Vacunas novedosas contra sub-tipos multiples de virus de influenza. |
WO2009092038A1 (en) * | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
US9764024B2 (en) | 2008-11-28 | 2017-09-19 | Statens Serum Institut | Optimized influenza vaccines |
US10022431B2 (en) | 2010-02-10 | 2018-07-17 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US9517258B2 (en) * | 2012-03-15 | 2016-12-13 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
CN105219773B (zh) * | 2013-12-25 | 2017-09-26 | 北京大北农科技集团股份有限公司 | 嵌合启动子及其用途 |
CN103901209B (zh) * | 2014-02-18 | 2016-05-25 | 王明丽 | 一种重组蛋白ie1包被酶标反应板的制备方法及定量检测人血浆hcmv中和抗体试剂盒 |
US10441643B2 (en) | 2014-03-19 | 2019-10-15 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP3119427B1 (en) | 2014-03-19 | 2018-12-26 | Mayo Foundation for Medical Education and Research | Methods and materials for treating cancer |
CN105120042B (zh) * | 2015-09-09 | 2019-02-12 | 小米科技有限责任公司 | 移动终端 |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
WO2019217473A1 (en) * | 2018-05-07 | 2019-11-14 | The Administrators Of The Tulane Educational Fund | Mutant e. coli enterotoxins as anti-inflammatory agents |
US20240084267A1 (en) * | 2021-01-12 | 2024-03-14 | Duke University | Compositions and methods for the genetic manipulation of the influenza virus |
WO2024097894A1 (en) * | 2022-11-04 | 2024-05-10 | RNAimmune, Inc. | Compositions and methods of ribonucleic acid vaccines encoding nye-so-1 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3431140A1 (de) * | 1984-08-24 | 1986-03-06 | Behringwerke Ag, 3550 Marburg | Enhancer fuer eukaryotische expressionssysteme |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5100792A (en) * | 1984-11-13 | 1992-03-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues |
US5168062A (en) * | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5120657A (en) * | 1986-12-05 | 1992-06-09 | Agracetus, Inc. | Apparatus for genetic transformation |
US5204253A (en) * | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
US5149655A (en) * | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
TW404844B (en) * | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
ES2247248T3 (es) * | 1994-01-21 | 2006-03-01 | Powderject Vaccines, Inc. | Instrumento de administracion de genes movido por gas comprimido. |
US5527928A (en) * | 1994-09-30 | 1996-06-18 | Nantz; Michael H. | Cationic transport reagents |
GB0027088D0 (en) * | 2000-11-06 | 2000-12-20 | Glaxo Group Ltd | DNA expression vectors |
ATE323166T1 (de) * | 2000-10-13 | 2006-04-15 | Chiron Corp | Fragmente der intron a von citomegalovirus |
AU2001297988B2 (en) * | 2000-11-27 | 2006-10-26 | Powderject Vaccines, Inc. | Nucleic acid adjuvants |
GB0118367D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxosmithkline Biolog Sa | Novel use |
BRPI0415202A (pt) * | 2003-10-10 | 2006-12-05 | Powderject Vaccines Inc | método de eliciar uma resposta de célula t contra um epìtopo de célula t em um indivìduo mamìfero hospedeiro, ensaio para testar a eficácia de um método de eliciar uma resposta de célula t, e, kit para realizar os mesmos |
EA010056B1 (ru) * | 2003-10-10 | 2008-06-30 | Паудерджект Вэксинс, Инк. | Конструкции нуклеиновых кислот |
-
2005
- 2005-04-20 GB GBGB0507997.5A patent/GB0507997D0/en not_active Ceased
-
2006
- 2006-02-01 MX MX2007009164A patent/MX2007009164A/es unknown
- 2006-02-01 EA EA200701643A patent/EA011557B1/ru not_active IP Right Cessation
- 2006-02-01 AU AU2006210716A patent/AU2006210716A1/en not_active Abandoned
- 2006-02-01 WO PCT/GB2006/000344 patent/WO2006082398A2/en active Application Filing
- 2006-02-01 CA CA002596731A patent/CA2596731A1/en not_active Abandoned
- 2006-02-01 AP AP2007004137A patent/AP2007004137A0/xx unknown
- 2006-02-01 BR BRPI0607119-8A patent/BRPI0607119A2/pt not_active IP Right Cessation
- 2006-02-01 US US11/815,278 patent/US20100221349A1/en not_active Abandoned
- 2006-02-01 SG SG201000360-6A patent/SG158902A1/en unknown
- 2006-02-01 CN CNA2006800110768A patent/CN101155597A/zh active Pending
- 2006-02-01 EP EP06704134A patent/EP1850869A2/en not_active Withdrawn
- 2006-02-01 KR KR1020077019899A patent/KR20070100403A/ko not_active Application Discontinuation
- 2006-02-01 JP JP2007552730A patent/JP2008528020A/ja active Pending
-
2007
- 2007-07-17 IL IL184653A patent/IL184653A0/en unknown
- 2007-07-30 TN TNP2007000295A patent/TNSN07295A1/en unknown
- 2007-07-30 NI NI200700191A patent/NI200700191A/es unknown
- 2007-08-28 MA MA30172A patent/MA29274B1/fr unknown
- 2007-08-30 NO NO20074421A patent/NO20074421L/no not_active Application Discontinuation
- 2007-08-31 ZA ZA200707522A patent/ZA200707522B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP1850869A2 (en) | 2007-11-07 |
JP2008528020A (ja) | 2008-07-31 |
GB0507997D0 (en) | 2005-05-25 |
CA2596731A1 (en) | 2006-08-10 |
NO20074421L (no) | 2007-10-31 |
US20100221349A1 (en) | 2010-09-02 |
AU2006210716A1 (en) | 2006-08-10 |
SG158902A1 (en) | 2010-02-26 |
TNSN07295A1 (en) | 2008-12-31 |
IL184653A0 (en) | 2007-12-03 |
MX2007009164A (es) | 2008-03-13 |
ZA200707522B (en) | 2008-08-27 |
NI200700191A (es) | 2008-02-05 |
MA29274B1 (fr) | 2008-02-01 |
CN101155597A (zh) | 2008-04-02 |
WO2006082398A2 (en) | 2006-08-10 |
WO2006082398A3 (en) | 2006-10-19 |
EA200701643A1 (ru) | 2008-02-28 |
EA011557B1 (ru) | 2009-04-28 |
AP2007004137A0 (en) | 2007-08-31 |
KR20070100403A (ko) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607119A2 (pt) | construção de ácido nucleico, população de construções de ácido nucleico, seqüência promotora quimérica isolada purificada, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìcula, dispositivo de liberação mediada por partìcula, composição farmacêutica, composição de vacina, e, método in vitro de obter a expressão em células de mamìfero de um polipeptìdeo da influenza de interesse | |
CN110121352B (zh) | Gold优化的car t-细胞 | |
US20210340530A1 (en) | Compositions and Methods for Immunotherapy | |
EP2961262B1 (en) | Talen-based gene correction | |
BRPI0415204A (pt) | construção de ácido nucleico, métodos de obtenção da expressão em células de mamìferos de um polipeptìdeo de interesse, e de imunização com ácido nucleico, partìculas revestidas, receptáculo de dosagem para um dispositivo de liberação mediada por partìculas, dispositivo de liberação mediada por partìculas, e, sequência de promotor quimérico isolada purificada | |
CA3091478A1 (en) | Compositions and methods for membrane protein delivery | |
ES2732774T3 (es) | UTR que aumentan la eficacia de la traducción de las moléculas de ARN | |
US20210038744A1 (en) | Use of lentiviral vectors expressing factor viii | |
TW202102529A (zh) | 用於多肽表現之多核苷酸、組合物及方法 | |
TW202039855A (zh) | 表現因子ix之慢病毒載體的用途 | |
IL303506A (en) | Polynucleotides, compounds and methods for genome editing involving deamination | |
US20230374456A1 (en) | T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy | |
US20230383253A1 (en) | Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy | |
WO2020106772A1 (en) | Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency | |
CA3206484A1 (en) | Engineered t cells | |
US20230383252A1 (en) | Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy | |
US20240228577A1 (en) | Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy | |
RU2803163C2 (ru) | Применение лентивирусных векторов, экспрессирующих фактор viii | |
TW202325848A (zh) | 用於基因體編輯之多核苷酸、組合物及方法 | |
US20240229096A1 (en) | Recombinant cell and method for producing endogenous polypeptide | |
JP6830651B2 (ja) | ペプチド、ポリヌクレオチド、ベクター、形質転換体、NFκB阻害剤、及びNFκB亢進性疾患の治療剤 | |
WO2024006955A1 (en) | Engineered t cells | |
WO2023028471A1 (en) | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013. |